View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBlueprint Medicines 과거 순이익 실적과거 기준 점검 0/6Blueprint Medicines 의 수입은 연평균 -12.6%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 18.5%의 비율로 증가했습니다. 매출은 연평균 3.9%의 비율로 감소해 왔습니다.핵심 정보-12.57%순이익 성장률-11.07%주당순이익(EPS) 성장률Biotechs 산업 성장률14.79%매출 성장률-3.94%자기자본이익률-45.52%순이익률-27.70%최근 순이익 업데이트31 Mar 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 18+ 1 more updateBlueprint Medicines Corporation Announces Directorate and Committee ChangesBlueprint Medicines Corporation (the “Company”), on June 2, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with SANOFI, a French soci é t é anonyme (“Parent”), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (“Aventis”), and Rothko Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Aventis (“Purchaser”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Jeffrey W. Albers, Daniella Beckman, Alexis Borisy, Lonnel Coats, Habib Dable, Mark Goldberg, M.D., Kathryn Haviland, Lynn Seely, M.D., and John Tsai, M.D.) resigned from his or her respective position as a member of the Company’s board of directors and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Michael J. Tolpa, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company.공고 • Jul 17Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from NASDAQ Biotechnology IndexBlueprint Medicines Corporation has been dropped from the NASDAQ Biotechnology Index.공고 • Jun 13Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesBlueprint Medicines Corporation announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®?/AYVAKYT®? (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM: As previously presented, AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3%) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM: AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM: PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells.공고 • Jun 02Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion on June 2, 2025. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Sanofi will pay $344.237175 million for 2.549905 million for Restricted stock units. Sanofi will pay $39.868875 million for 0.295325 million for Performance-based restricted stock units. Sanofi will pay $413.578677 million for 6.925296 million options. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The consummation of the tender offer is subject to customary closing conditions, including the tender of a number of shares of Blueprint common stock representing at least a majority of the outstanding shares of Blueprint common stock, the receipt of required regulatory approvals, and other customary conditions. Sanofi currently expects to complete the acquisition in the third quarter of 2025. Sanofi plans to finance the transaction with a combination of cash on hand and proceeds from new debt. The tender offer is not subject to any financing condition. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026. Upon termination of the Merger Agreement, (i) Sanofi under specified circumstances, including termination following a final order, decree or ruling arising in connection with certain antitrust or foreign investment laws, will be required to pay the Blueprint Medicines a termination fee in the amount of $500 million; and (ii) Blueprint Medicines under specified circumstances, including termination by the Blueprint Medicines to accept and enter into an agreement with respect to a superior proposal, will be required to pay Parent a termination fee in the amount of $318 million. The Company Board unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are advisable and fair to, and in the best interests of, the Company and the holders of the Shares, (ii) adopted the Merger Agreement and approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger, and (iii) resolved to recommend that the holders of the Shares accept the Offer and tender their Shares pursuant to the Offer and the transaction is subject to approval of Blueprint Medicines. Michael J. Aiello; Sachin Kohli of Weil, Gotshal & Manges LLP, Paris served as legal advisor to Sanofi, and Stuart M. Cable, Lisa R. Haddad and James Ding of Goodwin Procter LLP served as legal advisor to Blueprint Medicines. Centerview Partners LLC acted as financial advisor to Blueprint Medicines Corporation.매출 및 비용 세부 내역Blueprint Medicines가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BIT:1BPMC 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 25562-15637234531 Dec 24509-6735934130 Sep 24434-12834235530 Jun 24363-20532537831 Mar 24282-28830840431 Dec 23249-50729542830 Sep 23216-55528044830 Jun 23226-55426546831 Mar 23205-58125148631 Dec 22204-55823747730 Sep 22272-71822871630 Jun 22230-70222067331 Mar 22221-65021062431 Dec 21180-64419560130 Sep 21107-41118432230 Jun 2182834017148731 Mar 2180932516440731 Dec 2079431415832730 Sep 2081133314724930 Jun 2075-395136031 Mar 2072-371115031 Dec 1967-3489633130 Sep 1916-36278030 Jun 198-34064031 Mar 1944-26755031 Dec 1845-23748030 Sep 1845-20542030 Jun 1852-17038031 Mar 1817-17732031 Dec 1721-14828030 Sep 1727-12025030 Jun 1726-9922031 Mar 1727-8520031 Dec 1628-7219030 Sep 1625-6718030 Jun 1622-6317031 Mar 1618-5816031 Dec 1511-5614030 Sep 157-5714030 Jun 153-5611031 Mar 151-5290양질의 수익: 1BPMC 은(는) 현재 수익성이 없습니다.이익 마진 증가: 1BPMC는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 1BPMC은 수익성이 없으며 지난 5년 동안 손실이 연평균 12.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 1BPMC의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 1BPMC은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(-2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 1BPMC는 현재 수익성이 없으므로 자본 수익률이 음수(-45.52%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/07/17 02:38종가2025/07/17 00:00수익2025/03/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Blueprint Medicines Corporation는 10명의 분석가가 다루고 있습니다. 이 중 19명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관George FarmerBMO Capital Markets Equity ResearchDane LeoneBTIGArlinda LeeCanaccord Genuity7명의 분석가 더 보기
공고 • Jul 18+ 1 more updateBlueprint Medicines Corporation Announces Directorate and Committee ChangesBlueprint Medicines Corporation (the “Company”), on June 2, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with SANOFI, a French soci é t é anonyme (“Parent”), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (“Aventis”), and Rothko Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Aventis (“Purchaser”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Jeffrey W. Albers, Daniella Beckman, Alexis Borisy, Lonnel Coats, Habib Dable, Mark Goldberg, M.D., Kathryn Haviland, Lynn Seely, M.D., and John Tsai, M.D.) resigned from his or her respective position as a member of the Company’s board of directors and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Michael J. Tolpa, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company.
공고 • Jul 17Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from NASDAQ Biotechnology IndexBlueprint Medicines Corporation has been dropped from the NASDAQ Biotechnology Index.
공고 • Jun 13Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesBlueprint Medicines Corporation announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®?/AYVAKYT®? (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM: As previously presented, AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3%) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM: AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM: PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells.
공고 • Jun 02Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion on June 2, 2025. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Sanofi will pay $344.237175 million for 2.549905 million for Restricted stock units. Sanofi will pay $39.868875 million for 0.295325 million for Performance-based restricted stock units. Sanofi will pay $413.578677 million for 6.925296 million options. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The consummation of the tender offer is subject to customary closing conditions, including the tender of a number of shares of Blueprint common stock representing at least a majority of the outstanding shares of Blueprint common stock, the receipt of required regulatory approvals, and other customary conditions. Sanofi currently expects to complete the acquisition in the third quarter of 2025. Sanofi plans to finance the transaction with a combination of cash on hand and proceeds from new debt. The tender offer is not subject to any financing condition. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026. Upon termination of the Merger Agreement, (i) Sanofi under specified circumstances, including termination following a final order, decree or ruling arising in connection with certain antitrust or foreign investment laws, will be required to pay the Blueprint Medicines a termination fee in the amount of $500 million; and (ii) Blueprint Medicines under specified circumstances, including termination by the Blueprint Medicines to accept and enter into an agreement with respect to a superior proposal, will be required to pay Parent a termination fee in the amount of $318 million. The Company Board unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are advisable and fair to, and in the best interests of, the Company and the holders of the Shares, (ii) adopted the Merger Agreement and approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger, and (iii) resolved to recommend that the holders of the Shares accept the Offer and tender their Shares pursuant to the Offer and the transaction is subject to approval of Blueprint Medicines. Michael J. Aiello; Sachin Kohli of Weil, Gotshal & Manges LLP, Paris served as legal advisor to Sanofi, and Stuart M. Cable, Lisa R. Haddad and James Ding of Goodwin Procter LLP served as legal advisor to Blueprint Medicines. Centerview Partners LLC acted as financial advisor to Blueprint Medicines Corporation.